|Bid||40.24 x 0|
|Ask||41.06 x 0|
|Day's range||39.79 - 40.86|
|52-week range||31.03 - 51.34|
|Beta (5Y monthly)||1.28|
|PE ratio (TTM)||13.03|
|Forward dividend & yield||0.88 (2.20%)|
|Ex-dividend date||25 May 2021|
|1y target est||N/A|
Cara Therapeutics (NASDAQ: CARA) recently scored a key win with Food and Drug Administration approval of Korsuva in treating pruritis associated with chronic kidney disease for patients on hemodialysis. In this Motley Fool Live video recorded on Aug. 25, 2021, Motley Fool contributors Keith Speights and Brian Orelli discuss whether or not Cara stock is a buy after the big news. Another biotech had some good news on the FDA front: Cara Therapeutics, ticker there is CARA, and its partner Vifor Pharma (OTC: GNHAY) announced on Monday that the FDA had approved Korsuva for trading moderate to severe pruritus associated with chronic kidney disease, and this is in adults undergoing dialysis.
German healthcare group Fresenius raised 2021 targets though it saw a weaker third quarter, saying progress on its cost-cutting plan should offset troubles at its dialysis unit. The COVID-19 pandemic has affected healthcare groups in different ways as demand for coronavirus-related products and services coincided with the evolution of new coronavirus variants and higher rates of patient deaths. Fresenius said that while it earlier expected lower pandemic effects in late 2021, new coronavirus variants and exposure to high-risk patients at its dialysis unit Fresenius Medical Care could threaten those assumptions in the third quarter.
We often see insiders buying up shares in companies that perform well over the long term. The flip side of that is that...